Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center Study.

Hematological oncology·2026
Same author

Precision Aptamers Against a Native GPCR through Ligand-Guided Selection.

bioRxiv : the preprint server for biology·2026
Same author

T-Cell Clonal Expansion in Peripheral Blood Following Interventional Radiology Procedures for Metastatic Liver Cancer.

Cancers·2026
Same author

Targeted cellular micropharmacies deliver therapeutic agents to the brain.

EMBO molecular medicine·2026
Same author

Trispecific targeting of T cells engineered with TCR mimic antibodies to limit antigen escape.

Journal for immunotherapy of cancer·2026
Same author

Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same journal

Aptamers: Current Applications in Leukemia Diagnostics and Therapeutics.

Nucleic acid therapeutics·2026
Same journal

Exploring Clearance Pathways for GalNAc-siRNAs: Insights into Intracellular Kinetics and Therapeutic Implications.

Nucleic acid therapeutics·2026
Same journal

Unraveling the Stereochemical Complexity of Phosphorothioate-Modified Oligonucleotides Using Analytical Technologies.

Nucleic acid therapeutics·2026
Same journal

Rat and Rabbit Whole-Embryo Culture as a New Approach Method for Unlabeled Therapeutic Antisense Oligonucleotide Hazard Identification with No Requirement for Microinjection or Assisted Transfection.

Nucleic acid therapeutics·2026
Same journal

Programmable RNA Editing via Adenosine Deaminase Acting on RNA Enzymes: Current Advances and Clinical Potential.

Nucleic acid therapeutics·2026
Same journal

Efficient Downregulation of Flt-1 Mediated by Splice Switching ASO in Murine Endothelial Cells.

Nucleic acid therapeutics·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction
03:38

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction

Published on: October 6, 2022

A self-assembling short oligonucleotide duplex suitable for pretargeting.

Prabodhika Mallikaratchy1, Jeffery Gardner, Lars Ulrik R Nordstrøm

  • 1Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, New York 10065, USA.

Nucleic Acid Therapeutics
|July 16, 2013
PubMed
Summary
This summary is machine-generated.

This study introduces a novel RNA-based system for pretargeted drug delivery using monoclonal antibodies (mAbs). This approach improves drug delivery by combining slowly clearing mAbs with rapidly clearing RNA molecules for enhanced targeting.

More Related Videos

Split Hybridization Probe Utilizing a DNA Fluorescent Light-up Aptamer as a Signal Reporter for Sequence-Specific Nucleic Acid Analysis
07:10

Split Hybridization Probe Utilizing a DNA Fluorescent Light-up Aptamer as a Signal Reporter for Sequence-Specific Nucleic Acid Analysis

Published on: July 8, 2025

DNA-Tethered RNA Polymerase for Programmable In vitro Transcription and Molecular Computation
09:26

DNA-Tethered RNA Polymerase for Programmable In vitro Transcription and Molecular Computation

Published on: December 29, 2021

Related Experiment Videos

Last Updated: May 9, 2026

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction
03:38

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction

Published on: October 6, 2022

Split Hybridization Probe Utilizing a DNA Fluorescent Light-up Aptamer as a Signal Reporter for Sequence-Specific Nucleic Acid Analysis
07:10

Split Hybridization Probe Utilizing a DNA Fluorescent Light-up Aptamer as a Signal Reporter for Sequence-Specific Nucleic Acid Analysis

Published on: July 8, 2025

DNA-Tethered RNA Polymerase for Programmable In vitro Transcription and Molecular Computation
09:26

DNA-Tethered RNA Polymerase for Programmable In vitro Transcription and Molecular Computation

Published on: December 29, 2021

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Monoclonal antibodies (mAbs) offer high specificity but suffer from poor pharmacokinetics due to their large size.
  • Multistep administration strategies are explored to overcome pharmacokinetic limitations of mAbs.
  • Pretargeting approaches aim to improve drug delivery by separating the targeting molecule from the payload.

Purpose of the Study:

  • To develop and evaluate a novel pretargetable RNA-based system for drug delivery.
  • To assess the in vivo hybridization efficiency of a locked nucleic acid (LNA) and 2'O-Methyloligoribonucleotide (2'OMe-RNA) duplex.
  • To demonstrate the feasibility of using this system with a model antibody, rituximab.

Main Methods:

  • Design and synthesis of a pretargetable RNA system using LNA and 2'OMe-RNA.
  • Conjugation of rituximab (an mAb) to a 2'OMe-RNA strand (oligo).
  • In vivo administration and evaluation of the hybridization between the rituximab-oligo conjugate and a complementary LNA strand (c-oligo).

Main Results:

  • The LNA/2'OMe-RNA duplex demonstrated fast hybridization, high melting temperatures, excellent affinity, and high nuclease stability.
  • In a prototype model, the LNA-based complementary strand (c-oligo) effectively hybridized with the rituximab-oligo conjugate circulating in vivo.
  • Successful hybridization was observed despite the rapid clearance rate of the c-oligo.

Conclusions:

  • The developed LNA/2'OMe-RNA system is a promising platform for pretargeted delivery applications.
  • This RNA-based system offers a viable solution to improve the pharmacokinetic properties of mAb-based therapies.
  • The study validates the potential of this novel approach for targeted drug delivery and imaging.